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Be the Change: Advancing Lung Health and Closing the Global
Healthcare Gap
“I alone cannot change the world, but I can cast a stone across the
waters to create many ripples.”
—Mother Teresa

Chronic respiratory disease is the leading cause of disability and death
globally, and the ﬁgures are truly staggering:
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Asthma affects more than 350 million people and is the most
prevalent chronic illness of childhood worldwide.
Mild to moderate chronic obstructive pulmonary disease
afflicts approximately 200 million and claims the lives of
3.2 million each year, making it the third leading cause of
death globally.
Acute lower respiratory infections account for approximately
2.4 million deaths annually.
Lung cancer claims the lives of nearly 2 million people
each year, making it the leading cause of cancer-related
deaths (1).
Approximately 1.5 million tuberculosis-related deaths occur
each year (2).

And millions more live with debilitating respiratory illnesses
such as sleep-disordered breathing and occupational lung disease.
Furthermore, respiratory-related health issues have been exacerbated
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by coronavirus disease (COVID-19). For example, in 2019,
tuberculosis was responsible for 1.5 million deaths, making it the 10th
leading cause of death worldwide. According to the World Health
Organization’s 2021 Global Tuberculosis Report, the COVID-19
pandemic has unraveled years of global progress in tackling
tuberculosis, as related deaths increased for the ﬁrst time in more
than 10 years because of health care and supply chain disruptions
during the pandemic (2): indirect yet important factors to consider
when reﬂecting on the current state of global lung health. Finally,
climate change is starting to have unmistakable impacts on global
lung health.
Although most chronic respiratory diseases are
preventable and treatable, low- and middle-income countries
carry a disproportionate burden of the global morbidity and
mortality rates. According to the World Health Organization,
there is a strong correlation between chronic respiratory
diseases and poverty. Chronic respiratory diseases contribute
to complex multimorbidities, and lower track respiratory
infections, chronic obstructive pulmonary disease, and
tuberculosis are among the top 10 leading causes of death in
low- and middle-income countries. Limited access to health
education, health and screening services, and vaccines, as well
as low literacy rates and greater exposure to harmful
environmental toxins, are major obstacles to appropriate
health care delivery in these countries.
With more than 15,000 members representing 130
countries, the American Thoracic Society (ATS) has a broad
international reach and platform to help level the global lung
health landscape and advance our mission “to accelerate global
innovation in the advancement of respiratory health through
multidisciplinary collaboration, education, and advocacy.” On
September 25, World Lung Day, the ATS will join our Forum
of International Respiratory Societies (FIRS) partners to help
focus on these global health disparities. This day is an
important reminder of the need to elevate the importance of
lung health and disease awareness and our responsibility to
engage in advocacy and action that will affect future
generations.
As an international society, we provide members with
opportunities to get involved locally and collaborate globally
with researchers, academicians, and public health professionals
to champion change, as outlined below.
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It only takes a spark to light a fire, one person to inspire
countless others. Philip Hopewell, M.D., exemplifies this
very notion. His lifelong service to patients and
extraordinary contributions to the medical research
community continue to inspire investigators worldwide. The
Philip Hopewell Prize for Global Respiratory Health
Research, established in his honor, provides support to
midcareer investigators in low- and middle-income
countries and nurtures them to become established leaders
in global respiratory health research, a prime example of
how one’s dedication to improving lung health can create a









legacy that will continue to motivate others to combat
health disparities and affect change on a global scale.
As philosopher Thomas Hobbes said, “scientia potentia est”:
knowledge is power. Through the pursuit of knowledge and
the advancement of research, we make great strides in
improving global health. For nearly 30 years, the ATS
MECOR Program has worked to develop lung disease
research in low- and middle-income countries at the local and
regional levels. To date, more than 1,800 graduates have
participated in the program’s worldwide network of multilevel
research methods and training courses, which prepare them to
design and conduct research relevant to the needs of the
settings in which they work.
Investing in the future is essential to maintaining
momentum in lung health research, identifying health
disparities, and improving patient care for all. With ATS
International Trainee Scholarships, we can grant financial
support to trainees around the world; connect them with
fellow trainees, scientists, and mentors in their areas of
research; and provide access to state-of-the-art clinical
research. Trainees can also travel to the ATS International
Conference to present their research to respiratory health
professionals from abroad.
The ATS community is in an ideal position to influence
change and help shape global health policy through advocacy
for international programs. For nearly a decade, ATS
members have traveled to Capitol Hill in Washington, DC,
for the Annual ATS Hill Day, where they gain insight on key
issues and advocate for lung health at all federal government
levels. From the executive branch to Congress and the courts,
our members advocate for global health care on behalf of
physicians, scientists, health professionals, and, of course,
the patients they serve.
Through our partnership with FIRS, collaborations with
peer societies on joint webinars addressing challenges and
opportunities in lung health, the dissemination of research
via our four scientific journals, and knowledge sharing at
the ATS International Conference, the ATS is committed to
doing its part to address disparities, close the health care
gap, and improve lung health for all.

On this World Lung Day, we invite and encourage each of you
to do your part: explore the vast resources provided by the ATS, FIRS,
the World Health Organization, and our peer societies; participate in
learning opportunities; be a mentor; reach out to colleagues and join
the conversation; advocate for health equity; and take every
opportunity to get involved. When we work together, the potential
for positive change is limitless.
To learn more about ATS initiatives and how you can get
involved, visit the ATS website. Also, be sure to follow the
conversation on social media. 䊏
Author disclosures are available with the text of this article at
www.atsjournals.org.
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Lung Health for All: Chronic Obstructive Lung Disease
and World Lung Day 2022
“Lung Health for All” is the key theme of World Lung Day
2022 (September 25). The day aims to highlight the global
burden of the major respiratory diseases and the impact
of coronavirus disease (COVID-19), with a focus on low- and
middle-income countries (LMIC). Key messages for the day
are the importance of early detection and reduction of
inequalities. These align well with the objectives Global
Initiative for Chronic Obstructive Lung Disease (GOLD) of
improving the diagnosis and management of chronic
obstructive pulmonary disease (COPD) around the world.
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COPD affects 1 in 10 of the adult global population and is
one of the three commonest causes of death worldwide (1).
It is also a major cause of the global inequalities in health
and is more prevalent where such inequalities are more
extreme.
In 2019 COPD killed 3.22 million people (2), and the
number of deaths rose by 17.5% between 2007 and 2017 (3).
The main burden of mortality from COPD is seen in Latin
America, sub-Saharan Africa, India, China, and Southeast
Asia. The Global Burden of Disease study estimated that
COPD affected 104.7 million men and 69.7 million women
globally in 2015 and that between 1990 and 2015 the
prevalence of COPD had increased by 44.2% (4); however,
another analysis has estimated that COPD is much more
common and that 384 million people had COPD in 2010 (5).
Until recently the mean life expectancy of the population in
many LMIC has been poor and survival to an age when
COPD would usually be diagnosed was uncommon, but
improvements in life expectancy in LMIC over the last 50
years, together with reductions in childhood mortality, are
669

